Educational Activities Archives

Opioid use disorder (OUD) among women and people who become pregnant is increasing in prevalence in clinical settings. The standard of care is to provide buprenorphine or methadone as a part of a complete treatment approach during pregnancy and beyond the postpartum period. This module reviews the historical and current context of opioid use among women and birthing people during pregnancy. It compares pharmacological treatment options for women and people who become pregnant with an OUD and also discusses the issues with detoxification or medically assisted withdrawal from opioids during pregnancy. Issues related to the treatment of OUD during pregnancy and in the postpartum period for the birthing person, fetus and child will also be discussed (e.g., induction, dosing, pain management, neonatal withdrawal and how to reduce its severity).

Join our 4-session online case-based learning collaborative series focused on treating opioid use disorder. Delve into best practices on OUD and Pregnancy and explore real-world cases provided by addiction experts, applying knowledge to practical situations. Each session is presented live online and spans 1.5 hours.

View Guidance.

Opioid use disorder (OUD) can be a fatal addiction with complex implications for new and/or expecting mothers. OUD challenges can lead to many complications for mother and child, including low birth weight, clinical challenges with medical dosing and increased risk of accidental death. In the U.S. alone, a baby is born passively dependent every 15 minutes. To ensure best health outcomes for both mother and child, policies must allow engagement in evidence-based treatment and protect clients from legal ramifications. Hear from a physician, clinic director and an individual with lived experience to broaden understandings about the treatment and policy landscape for pregnant and postpartum women with OUD.

This webinar will review variations on buprenorphine dosing that can be considered for patients with opioid use disorder involving fentanyl. The presenters will review the evidence for and describe low dose buprenorphine initiation of protocols, high dose buprenorphine initiation of protocols, approaches to help support patients stop using full agonist opioids for a longer period of time, and a clinical approach to referring patients to alternative medications for opioid use disorder.

“The purpose of this checklist is for the dental patient (or guardian) and the dental provider to review their roles and responsibilities for safely using, storing, and disposing of opioid (or other controlled substance) prescriptions. A controlled substance is a medication or other drug that the United States Drug Enforcement Administration (DEA) has identified as having a high potential for misuse, addiction and/or dependency.”